Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review

Neil W. Anderson, Matthew J. Binnicker, Dana M. Harris, Razvan M. Chirila, Lisa Brumble, Jay Mandrekar, D. Jane Hata

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + ® Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.

Original languageEnglish
Pages (from-to)367-371
Number of pages5
JournalDiagnostic Microbiology and Infectious Disease
Volume85
Issue number3
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Keywords

  • Chronic obstructive pulmonary disease
  • RSV
  • Transplant

Fingerprint Dive into the research topics of 'Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review'. Together they form a unique fingerprint.

  • Cite this